Published in final edited form as:

Chem Res Toxicol. 2014 January 21; 27(1): 147–156. doi:10.1021/tx4004215.

Human Cytochrome P450 Oxidation of 5-Hydroxythalidomide and Pomalidomide, an Amino Analog of Thalidomide

Goutam Chowdhury^{†,§}, Norio Shibata, Hiroshi Yamazaki^{‡,*}, and F. Peter Guengerich^{†,*}

Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146, Graduate School of Engineering, Nagoya Institute of Technology, Showa-ku, Nagoya, 466-8555, Japan, and Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan

Abstract

The sedative and antiemetic drug thalidomide [α -(*N*-phthalimido)glutarimide] was withdrawn in the early 1960s due to its potent teratogenic effects but was approved for the treatment of lesions associated with leprosy in 1998 and multiple myeloma in 2006. The mechanism of teratogenicity of thalidomide still remains unclear, but it is well established that metabolism of thalidomide is important for both teratogenicity and cancer treatment outcome. Thalidomide is oxidized by various cytochrome P450 (P450) enzymes, the major being P450 2C19, to 5-hydroxy-, 5'-hydroxy-, and dihydroxythalidomide. We previously reported that P450 3A4 oxidizes thalidomide to the 5-hydroxy and dihydroxy metabolites, with the second oxidation step involving a reactive intermediate, possibly an arene oxide, that can be trapped by glutathione (GSH) to GSH adducts. We now show that the dihydroxythalidomide metabolite can be further oxidized to a quinone intermediate. Human P450s 2J2, 2C18, and 4A11 were also found to oxidize 5-hydroxythalidomide to dihydroxy products. Unlike P450s 2C19 and 3A4, neither P450 2J2, 2C18, nor 4A11 oxidized thalidomide itself. A recently approved amino analog of thalidomide, pomalidomide (CC-4047, ActimidTM), was also oxidized by human liver microsomes and P450s 2C19, 3A4, and 2J2 to the corresponding phthalimide ring-hydroxylated product.

Introduction

Thalidomide [α -(*N*-phthalimido)glutarimide] is a sedative and antiemetic drug originally introduced in the clinics in the 1950s. Due to its potent teratogenicity it was withdrawn in the early 1960s.¹ However, owing to its clinical properties it was approved in 1998 for the treatment of lesions associated with leprosy and in 2006 for multiple myeloma.^{2–4} In addition, thalidomide has been tested for the treatment of many diseases including refractory esophageal Crohn's disease, recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia, and oral lesions in the course of myelofibrosis.^{4–6} Two analogs

*Corresponding authors: Prof. F. Peter Guengerich, Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-0146, Telephone: 1 (615) 322-2261; FAX: 1 (615) 322-3141; f.guengerich@vanderbilt.edu. Prof. Hiroshi Yamazaki, Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan, Telephone: (81) 41-721-1406; FAX: (81) 41-721-1406; hyamazak@ac.shoyaku.ac.jp.

[†]Vanderbilt University School of Medicine

[‡]Showa Pharmaceutical University

[§]Nagoya Institute of Technology

Supporting Information Available

LC-MS/MS chromatograms showing lack of formation of hydroxythalidomide in the presence of P450 2J2 from (*R*)- or (*S*)-thalidomide, LC-MS/MS chromatogram and CID spectrum showing enhanced formation of the GSH conjugate of dihydroxythalidomide in the presence of P450 3A4 and tyrosinase, and LC-HRMS chromatogram and spectrum showing the presence and exact mass of hydroxypomalidomide formed in the presence of human liver microsomes. This material is available free of charge via the Internet at <http://pubs.acs.org>.

of thalidomide with increased potency and reduced toxicity, lenalidomide and pomalidomide, have also entered the clinics for the treatment of refractory multiple myeloma.^{7–9}

Because of the recent emergence of thalidomide as a drug with clinical potential, there is renewed interest in both its toxicity and pharmacological mechanisms. The teratogenicity of thalidomide is severe and also very species specific, being teratogenic in primates and rabbits but not in rats and mice. It was initially believed that the *R* isomer is sedative while the *S* isomer is teratogenic;^{10,11} however, the two enantiomers are readily interconvertible.¹² Although the teratogenicity of thalidomide is well established, the mechanism still remains unclear. Various hypotheses have been proposed including generation of reactive oxygen species, generation of reactive arene oxide and acylating intermediates, inhibition of angiogenesis, and inhibition of the protein cereblon.^{13–17}

Metabolism of thalidomide is important for both teratogenicity and anti-cancer efficacy.^{18,19} Thalidomide is metabolized by two major pathways, hydrolysis and P450-mediated oxidation (Scheme 1). Various P450s oxidize thalidomide to 5-hydroxy-, 5'-hydroxy-, and dihydroxythalidomide metabolites, the major being P450 2C19.^{20,21} Recently we reported that P450 3A4 and 3A5 also oxidize thalidomide to the 5-hydroxy and dihydroxy metabolites.^{22,23} The second oxidation step in the P450 3A4 pathway generates a reactive intermediate, possibly an arene oxide (as initially suggested by Gordon *et al.*¹⁵) that can be trapped by GSH to give GSH adducts.^{22,23} The formation of GSH adducts of 5-hydroxythalidomide was also confirmed in humanized mouse models.²⁴ Interestingly, lenalidomide is minimally metabolized to the 5-hydroxy and *N*-acetyl lenalidomide metabolites (each produced at < 5% of the total dose) with the majority of the dose being excreted unchanged in humans.²⁵ Pomalidomide has been shown to be extensively metabolized to various products, including two phthalimide ring-hydroxylated, one *N*-acetylated, and various hydrolysis products.²⁶

The P450s (EC 1.14.14.1) constitute a large superfamily of enzymes found throughout nature and function primarily as monooxygenases.²⁷ P450s are involved in the oxidation of a large number of compounds including fatty acids, sterols, fat-soluble vitamins, and xenobiotics. Drugs are metabolized primarily by P450s, and metabolism contributes to many of their pharmacological and toxicological actions.²⁸ The human liver is the major site of P450s, although other organs including intestine, lung, kidney, heart, skin, and brain also have P450s. P450 3A4 is the major P450 enzyme in human liver and small intestine; P450 2C19 is a relatively minor P450 in the liver, in terms of the amount of the protein.²⁸ The major P450 in the heart and cardiovascular system is P450 2J2,²⁹ 2C18 is a major P450 in the skin,^{30,31} and 3A7 is the dominant P450 in the fetus.³² Although the liver is the major site of drug metabolism, P450s in other organs can also metabolize drugs. For example, P450 2J2 oxidizes terfenadine and ebastine³³ and P450 2C18 oxidizes phenytoin.³⁴ Thus, extrahepatic bioactivation of xenobiotics to toxic products may be responsible for organ specific toxicity.

In our continuing efforts to understand the metabolism of thalidomide and its possible role in teratogenicity,^{22,23} we studied the biotransformation of thalidomide, its 5-hydroxy product, and the recently approved amino analog pomalidomide by P450s that are preferentially expressed in specific tissues. These three P450s were selected for several

reasons. P450 2J2 is primarily expressed in the endothelial cells of the intestine and the cardiovascular systems and also the myocardiocytes in the heart.^{35,36} It is also expressed in the liver, kidney and lung.²⁹ The major function of P450 2J2 is apparently epoxidation of arachidonic acid to the four regioisomers of epoxyicosatrienoic acid.³⁷ P450 2J2 has also been shown to also metabolize drugs including ebastin, terfenidine, and artemezole.³³ P450 2C18 is significantly expressed in the skin, although it is also expressed in other tissues.^{28,30,31} The antiepileptic drug phenytoin is oxidized by 2C18 to hydroxylated and (toxic) quinone products.³⁴ P450 4A11 is expressed in various tissues including the liver, kidney, and intestine.²⁸ The primary function of 4A11 is ω - and ω -1 hydroxylation of arachidonic acid.³⁸ Interestingly, all of these three P450s have been reported to be expressed in fetal tissues as well.^{39,40}

We found that P450s 2J2, 2C18, and 4A11 all oxidize 5-hydroxythalidomide to the corresponding dihydroxy product, although they are unable to metabolize thalidomide itself. The dihydroxythalidomide product is further oxidized to a potentially toxic quinone intermediate. We also report on the metabolism of the amino analog pomalidomide by several P450s. Pomalidomide (4-amino α -(*N*-phthalimido)glutarimide, Actimid®, CC-4047) is an amino analog of thalidomide with increased efficacy and reduced toxicity. It has recently been approved for the treatment of relapsed or refractory multiple myeloma.⁸ Pomalidomide is considered to be the most potent immunomodulatory drug in this class, 100 times more potent than thalidomide and 10 times than lenalidomide. The mechanism of action, however, is not fully understood but involves anti-angiogenic effects, immunomodulation, effects on the myeloma tumor microenvironment, and inhibition of the protein cereblon.⁷ In a recent report,²⁶ pomalidomide was shown to be metabolized in humans to the *ortho*- and *para*-phthalidimide ring-hydroxylated metabolites, along with *N*-acetylated and hydrolyzed products. However, in *in vitro* assays with purified enzymes the authors failed to detect any *para*-hydrothalidomide product.²⁶ With P450s 1A2, 2C19, 2D6, and 3A4 the *ortho*-hydroxythalidomide was detected as a metabolite, although the apparent rate of oxidation was very low. Because of our interest in tissue-specific metabolism (especially with respect to the antiangiogenic effect), we examined the metabolism of pomalidomide by P450 2J2 and compared it with P450s 2C19 and 3A4 and human liver microsomes.

Experimental Procedures

Chemicals

(*R*)-(+)-Thalidomide and (*S*)-(-)-thalidomide (SigmaAldrich, St. Louis, MO) and racemic pomalodomide (Selleck Chemicals, Houston, TX) were purchased from the indicated sources. 5-Hydroxythalidomide was synthesized as reported previously.⁴¹ Other chemicals and reagents used in this study were obtained from the sources described previously^{22–24} or were of the highest quality commercially available.

Enzyme Preparations

P450 2J2 and 2C18 Supersomes® (microsomes with P450s expressed in insect cells using baculovirus vectors) were obtained from BD Biosciences (San Jose, CA). Pooled human liver microsomes were prepared in 10 mM Tris-HCl buffer (pH 7.4) containing 0.10 mM EDTA and 20% (v/v) glycerol, as described previously.⁴² Recombinant human P450s, co-expressed with human NADPH-P450 reductase (EC 1.6.2.4) in *Escherichia coli* membranes, were prepared as described earlier.^{22,43} In some cases purified P450 proteins were reconstituted with purified (rat) recombinant NADPH-P450 reductase.⁴⁴ Microsomal protein concentrations were estimated using a bicinchoninic acid (BCA) protein assay (Pierce, Rockford, IL). P450 4A11 was heterologously expressed and purified as described

elsewhere.⁴⁵ Concentrations of total P450⁴⁶ and NADPH-P450 reductase⁴² were estimated spectrally as described previously.

Hydroxylation of Thalidomide and Pomalidomide

Thalidomide and pomalidomide hydroxylation activities were determined using LC-MS and LC-MS/MS. Briefly, a typical incubation mixture (total volume of 200 μ L) contained microsomal protein (1.0 mg mL⁻¹) or recombinant P450 (0.10 μ M, in bacterial membranes or in Supersomes® from insect cells) or reconstituted purified proteins (0.1–1 μ M in P450), an NADPH-generating system (0.25 mM NADP⁺, 2.5 mM glucose 6-phosphate, and 0.25 unit mL⁻¹ yeast glucose 6-phosphate dehydrogenase),⁴² and thalidomide or pomalidomide (0.1–0.2 mM) in 0.10 M potassium phosphate buffer (pH 7.4), unless otherwise specified. For P450 activity determinations, incubations were carried out at 37 °C for 30–60 min. Incubations were terminated by adding 0.20 mL of ice-cold CH₃CN or 10 μ L of acetic acid. The samples were centrifuged at 2×10^3 g for 10 min and the aqueous supernatant was analyzed using a LC-MS or LC-MS/MS systems, *vide infra*.

Oxidation of 5-Hydroxythalidomide by P450s 2J2, 2C18, and 4A11

A typical incubation mixture (total volume of 200 μ L) contained recombinant P450 2J2 or 2C18 (1.0 μ M) in Supersomes® or purified P450 4A11 protein (0.2 μ M) in a reconstituted system, an NADPH-generating system (0.25 mM NADP⁺, 2.5 mM glucose 6-phosphate, and 0.25 unit mL⁻¹ yeast glucose 6-phosphate dehydrogenase),⁴² and (*R*)- or (*S*)-5-hydroxythalidomide (0.1–0.2 mM) in 100 mM potassium phosphate buffer (pH 7.4). When indicated, GSH was added at 5 mM. Incubations were carried out at 37 °C for 60 min and terminated by adding 10 μ L of glacial CH₃CO₂H. The solution was centrifuged at 2×10^3 g for 10 min and the supernatant was analyzed using LC-MS/MS, *vide infra*.

LC-MS/MS Assays

LC-MS and LC-MS/MS analyses of the oxidation products were performed on a Waters Acquity ultra-performance liquid chromatography (UPLC) system (Waters, Milford, MA) connected to a Thermo LTQ mass spectrometer (Thermo Fisher, Waltham, MA) using an Acquity UPLC BEH octadecylsilane (C₁₈) column (2.1 mm $\times$ 50 mm). LC conditions were as follows: buffer A contained 10 mM NH₄CH₃CO₂ (pH 4.0) in 5% CH₃CN and 95% H₂O (v/v), and buffer B contained 10 mM NH₄CH₃CO₂ (pH 4.0) in 95% CH₃CN and 5% H₂O (v/v). The following gradient program was used, with a flow rate of 0.3 mL min⁻¹: 0–5 min, linear gradient from 100% A to 75% A (v/v); 5–5.5 min, linear gradient to 100% B; 5.5–7.5 min, hold at 100% B; 7.5–8 min, linear gradient to 100% A; 8–10 min, hold at 100% A. The temperature of the column was maintained at 40 °C. Samples (20 μ L) were infused with an auto-sampler. MS analyses were performed in the electrospray ionization (ESI) negative ion mode. The mass spectrometer was tuned using 5-hydroxythalidomide for thalidomide oxidation products or with pomalidomide for pomalidomide oxidation products. Product ion spectra were acquired over the range *m/z* 100–500 using an Acquity UPLC BEH octadecylsilane (C₁₈) column (2.1 mm $\times$ 50 mm). For initial characterization of the oxidation products a Thermo LTQ mass spectrometer was used; for kinetic analysis a Thermo Ultra Quantum mass spectrometer (Thermo Fisher, Waltham, MA) was used. Both instruments were connected to a Waters Acquity UPLC system (Waters, Milford, MA) and were operated in the negative ESI mode. Hydroxypomalidomide was quantified using the *m/z* 288 $\rightarrow$ 176 transition, compared with the *m/z* 273 $\rightarrow$ 161 transition of 5-hydroxythalidomide, due to lack of authentic standard. 5-Hydroxythalidomide was also used as an internal standard.

LC-MS and LC-MS/MS analyses of the GSH conjugates of hydroxythalidomide and dihydroxythalidomide were performed on a Waters Acquity UPLC system connected to a

Thermo LTQ mass spectrometer using either an Acquity UPLC BEH octadecylsilane (C₁₈) column (2.1 mm × 50 mm). LC conditions were as follows: buffer A contained 2% CH₃CN in H₂O (v/v), and buffer B contained 95% CH₃CN (v/v) with each containing 0.1% HCO₂H. For the UPLC column the following gradient program was used, with a flow rate of 0.3 mL min⁻¹: 0–5 min, linear gradient from 100% A to 75% A (v/v); 5–5.5 min, linear gradient to 100% B; 5.5–7.5 min, hold at 100% B; 7.5–8 min, linear gradient to 100% A; 8–10 min, hold at 100% A. The temperature of the column was maintained at 40 °C. Samples (10–20 µL) were infused with an autosampler. For GSH adduct detection the MS analyses were performed in the positive ion mode and the mass spectrometer was tuned using GSH.

LC-high-resolution mass spectrometry (HRMS) was performed on a Waters Acquity UPLC system connected with a Waters Synapt hybrid quadrupole/OA-TOF mass spectrometer equipped with a dual chemical ionization/ESI source. LC conditions were the same as mentioned in the previous section. MS analyses were performed in the positive ion mode for GSH adducts and negative ion mode for hydroxythalidomide. ESI conditions were as follows: capillary voltage 2.59 V, sampling cone 30, extraction cone 4.1, source temp 125 °C, desolvation temperature 325 °C, and Trap CE parameter of 6. Ion spectra were acquired over the range *m/z* 50–500 using the waters MassLynx V4.1 software.

Kinetic Analysis

Kinetic analysis was done using nonlinear regression analysis (Prism, GraphPad Software, La Jolla, CA). The Michaelis constant *K_m* and *k_{cat}* values were determined using hyperbolic substrate concentration-dependent velocity curves.

Results

Biotransformation of Thalidomide and 5-Hydroxythalidomide by P450s 2J2, 2C18, and 4A11

In vitro metabolism studies of thalidomide with P450s 2J2, 2C18 and 4A11 revealed that none of these enzymes are capable of metabolizing thalidomide (e.g., Supporting Information, Figure S1). However, when (*R*)-5-hydroxythalidomide was used as a substrate, all three of these P450 enzymes were able to metabolize it to a dihydroxythalidomide product, as detected by LC-MS and LC-MS/MS analysis (Figure 1). LC-MS analysis in the negative ion mode revealed formation of a peak at *t_R* 3.2–3.8 min with *m/z* 289, 16 a.m.u. higher than (*R*)-5-hydroxythalidomide. Collision-induced dissociation (CID) of the parent ion (*m/z* 289) yielded fragment ions with *m/z* 177, 218, and 246, which are consistent with the presence of a dihydroxythalidomide product with the two hydroxyl groups being present on the phenyl ring of phthalimide moiety of thalidomide (Figure 1D). Surprisingly, in the control reactions where an NADPH-generating system was not added, a small but detectable and reproducible peak with a similar *t_R* and mass and fragmentation pattern to dihydroxythalidomide was observed. This trace reaction may be due to non-enzymatic addition of H₂O to a tautomer of (*R*)-5-hydroxythalidomide followed by oxidation to the dihydroxythalidomide product (Scheme 2). The formation of the dihydroxythalidomide metabolite was also observed for the (*S*)-enantiomer (data not shown).

GSH Adduct Formation from 5-Hydroxythalidomide Oxidation Products

Oxidation of (*R*)-5-hydroxythalidomide by P450 2J2 in the presence of GSH (5 mM) resulted in the formation of 5-hydroxythalidomide-GSH adducts, similar to the case with P450 3A4.²² LC-MS and LC-MS/MS analysis (positive ion mode) led to the detection of a peak at *t_R* ~3.6 min with *m/z* 580, which is consistent with the presence of a GSH conjugate of 5-hydroxythalidomide (Figure 2A). Using LC-HRMS, the mass of the [M+H]⁺ ion of the *t_R* ~3.6 min peak was found to be 580.1344 (calculated [M+H]⁺ 580.1344). CID of the peak

at $t_R \sim 3.6$ min in the positive ion mode yielded fragment ions with m/z 505 (loss of 75) and 451 (loss of 129), typical of GSH conjugates (Figure 2B).⁴⁷ Together these results clearly indicate that oxidation of (*R*)-5-hydroxythalidomide by P450 2J2 generates a reactive intermediate that can be trapped by GSH to form a 5-hydroxythalidomide-GSH conjugate. GSH conjugates were also detected for the (*S*)-enantiomer (data not shown).

Oxidation of Dihydroxythalidomide to a Quinone Intermediate

Compounds containing the *ortho* and *para*-hydroxyphenol functionality (i.e., catechols and hydroquinones, respectively) are known to undergo non-enzymatic or P450-catalyzed oxidation to potentially toxic quinone intermediates. The hypothesis that dihydroxythalidomide may be oxidized to quinones led us to look for possible thalidomide quinone metabolites in the incubation mixtures. Incubations of (*R*)-5-hydroxythalidomide with NADPH-fortified P450 3A4 *E. coli* membranes for 3 h followed by LC-MS analysis led to the detection of a major peak at $t_R \sim 5.4$ min and a minor peak at $t_R \sim 5.5$ min in the LC-MS chromatogram (m/z 287 in the negative ion mode) (Figure 3). LC-MS/MS analysis of the $t_R \sim 5.4$ min peak in the negative ion mode gave fragment ions with m/z 244 and 175. These results are consistent with the presence of quinone metabolites of thalidomide. The quinone intermediates were also detected for the (*S*)-enantiomer (data not shown).

Trapping of the Quinone Intermediate of Thalidomide with GSH

Ortho- and *para*-quinones are known to react with electrophiles to form various adducts including GSH and protein adducts.⁴⁸ In order to obtain further evidence for the presence of the quinone metabolites, an experiment was performed to detect possible GSH adducts of dihydroxythalidomide. (*R*)-5-Hydroxythalidomide was incubated with NADPH-fortified P450 3A4 *E. coli* membranes or P450 2J2 Supersomes[®] in the presence of GSH for 3 h. LC-MS analysis of the reaction mixture in the positive ion mode revealed the presence of peaks at $t_R \sim 2.4$ for P450 3A4 and $t_R \sim 2.4$ and 3 min for P450 2J2 with m/z 596. CID of the peaks at $t_R \sim 2.4$ for P450 3A4 and $t_R \sim 3$ min for P450 2J2 (positive ion mode) yielded fragment ions with m/z 521 (loss of 75) and 467 (loss of 129), typical of GSH conjugates.⁴⁷ Based on the mass and fragmentation data it can be concluded that the t_R 2.4 and 3.0 min peaks correspond to dihydroxythalidomide-GSH conjugate(s). The enzyme tyrosinase oxidizes catechols to quinones, and its addition to the reaction mixture increased the yield of the GSH adducts (Figure S2, Supporting Information). GSH conjugates of the dihydroxythalidomide were also detected for the (*S*)-enantiomer (data not shown).

Pomalidomide Hydroxylation Catalyzed by Human Liver Microsomes and Recombinant P450s 2C19, 2J2, and 3A4

Incubation of racemic pomalidomide with NADPH-fortified microsomes, purified P450 2C19, P450 3A4 bicistronic *E. coli* membranes, or P450 2J2 Supersomes[®] at 37 °C for 1 h followed by LC-MS analysis gave a peak at $t_R \sim 3.1$ min with m/z 288 (negative ion mode) (Figure 5, Supporting Information Figure S3). CID of the m/z 288 ion (negative ion mode) gave characteristic fragment ions at m/z 176 and 245. Based on the fragmentation of dihydroxythalidomide, this compound corresponds to hydroxypomalidomide, with hydroxylation taking place either in the amino-phthalimide ring or on the amino group (Scheme 3). To further distinguish between these two structural possibilities, the products were treated with a bathochromic reagent that forms a color in the presence of hydroxylamines, detected by its visible absorbance spectroscopy (ϵ_{595} 32,900 M⁻¹ cm⁻¹).⁴⁹⁻⁵¹ In the case of pomalidomide we were unable to detect absorbance above background. Together these results suggest that pomalidomide is oxidized by P450 2C19, 3A4, and 2J2 and human liver microsomes to the ring-hydroxylated metabolite.

Kinetic Analysis of Pomalidomide Hydroxylation Catalyzed by Recombinant P450 2C19, 2J2, and 3A4 Enzymes

Kinetic analyses of P450 mediated pomalidomide hydroxylation were conducted with recombinant human P450s 2C19, 3A4, and 2J2 using LC-MS/MS in the single reaction monitoring (SRM) mode. The m/z 288 to 176 transition was utilized for quantitation of the product formed. Due to lack of authentic standards, 5-hydroxythalidomide was used as an internal standard and for quantitation. The apparent k_{cat} values for P450-mediated hydroxylation of racemic pomalidomide were found to be 0.5, 0.05, and 0.02 pmol/min/pmol P450 for P450s 2C19, 3A4, and 2J2, respectively (Table 1).

Discussion

Renewed interest in thalidomide has followed its recent approval for the treatment of leprosy and multiple myeloma.^{2,3} In addition, the potential use of thalidomide for other clinical conditions is being currently explored. However, the clinical use of thalidomide and other immunomodulatory drugs in this class has been tightly regulated because of their teratogenicity. The mechanism of teratogenicity of thalidomide is yet to be conclusively established. Various hypotheses have been proposed including oxidative stress, generation of reactive intermediates, inhibition of angiogenesis, and inhibition of the protein cereblon.^{13,14,17,52–54}

The involvement of reactive products has been entertained previously based on indirect evidence and even thought to be the cause for the anti-angiogenic effects of thalidomide. Using an *in vitro* activation/toxicity assay with purified epoxide hydrolase and the epoxide hydrolase inhibitor 1,1,1-trichloropropylene oxide, the presence of an epoxide intermediate was proposed (although direct evidence of action of epoxide hydrolase on an epoxide was not demonstrated).¹⁵ We have recently provided direct evidence for the P450 3A4 catalyzed formation of a reactive intermediate by detecting the GSH-conjugate of 5-hydroxythalidomide both *in vitro* and *in vivo*.^{22,23} However, it is unlikely that a reactive intermediate, capable of reacting with GSH (without conjugation catalyzed by GSH transferase) will travel from its site of formation in the liver to a potential site of action, the limb bud or the endothelial cells at site of angiogenesis. A recently proposed hypothesis, inhibition of the protein cereblon, currently seems to be the most popular proposal.¹⁷ Ito *et al.*¹⁷ reported non-covalent binding of thalidomide to the protein cereblon, part of a protein complex postulated to be important in development. Cereblon is a component of the E3 ubiquitin ligase complex (along with DDB1 and Cul4), involved with down-regulation of fibroblast growth factor and possibly the teratogenic effects associated with thalidomide.⁵⁴ Most of the experiments in the study by Ito *et al.*¹⁷ were done with 300 to 400 μM concentrations of thalidomide, which is inconsistent with the fact that a single dose of thalidomide during a time sensitive window is enough to cause teratogenicity.¹⁷ However, cereblon expression has been reported to be required for the antimyeloma activity of lenalidomide and pomalidomide.⁵⁴

Although the mechanism of teratogenicity of thalidomide remains to be conclusively established, considerable evidence suggests that metabolism of thalidomide is necessary for teratogenicity.^{18,19} However, previous metabolic studies of thalidomide did not provide any evidence to support this theory. In our effort to understand the metabolism of thalidomide and its possible association to teratogenicity and/or biological activity, we found that human P450s 2J2, 2C18, and 4A11 can oxidize 5-hydroxythalidomide to a corresponding and potentially toxic dihydroxythalidomide metabolite. Interestingly, none of these P450s metabolize thalidomide itself (e.g., Supporting Information Figure S3). Using a GSH trapping experiment we also found that the P450 2J2-catalyzed oxidation of 5-hydroxythalidomide involves the formation of a reactive intermediate that can be trapped

with GSH to give a GSH-5-hydroxythalidomide conjugate. This observation is consistent with the results obtained with P450 3A4.²² However, unlike P450 3A4, P450 2J2 does not oxidize thalidomide (Supporting Information Figure S3). Therefore, the presence of thalidomide should not interfere with the formation of the toxic metabolite or the reactive product by P450 2J2, 2C18, or 4A11.

Ortho- and *para*-hydroxyphenolic compounds undergo non-enzymatic or enzyme-catalyzed oxidation to the corresponding quinones, which can redox cycle to produce oxidative stress.⁴⁸ Because various P450s (including human P450s 3A4, 3A5, 2C19, 2J2, 2C18, and 4A11) can produce dihydroxythalidomide, we examined incubation mixtures for the presence of quinones using LC-MS/MS analysis. The presence of quinone products was further confirmed by detection of the GSH conjugate of dihydroxythalidomide. (We have been unsuccessful in establishing the sites of oxidation (in the catechol/quinones) due to the low yield and the need for NMR spectroscopy.) This thalidomide quinone metabolite resulting from the oxidation of the major metabolite, dihydroxythalidomide, may be the species responsible for the oxidative stress caused by thalidomide, as reported by Parman *et al.*¹⁴ One issue is whether enough of this could be generated to have a large impact in oxidative stress *in vivo*.

P450 2J2 is an enzyme found mainly in human extrahepatic tissues, with predominant expression in the endothelial cells of the cardiovascular systems and in lower levels in the intestine, kidney, lung, pancreas, brain, and liver.^{29,35,36} P450 2J2 has also been shown to be expressed in various human tumor cells and fetal tissue.^{39,55} Because angiogenesis involves generation of endothelial cells to form blood vessels, this preferential expression and P450 2J2-catalyzed formation of reactive intermediates may be involved in the anti-angiogenic and possibly teratogenic effect of thalidomide. A primary site of expression of P450 2C18 is the skin,^{30,31} which might be related to the clinical outcome of the treatment of the skin lesions associated with leprosy. In addition, P450 2C18 has been shown to metabolize phenytoin to a quinone intermediate, which is believed to be responsible for its teratogenic effect.³⁴ Although additional direct evidence is required to draw a conclusion regarding the involvement of reactive products in both the clinical and teratogenic effects of thalidomide, the evidence presented here is consistent with this possibility.

Pomalidomide, a recently approved analog of thalidomide, was also found to be metabolized by P450s 2C19, 2J2, and 3A4 to the corresponding hydroxy product (we were unable to rigorously determine the structure of the metabolite due to lack of an authentic standard and (for NMR) the low yields). We were not able to detect any quinoneimine intermediate or GSH-conjugate in our *in vitro* assays (data not shown). In a recently published human study,²⁶ pomalidomide was found to be metabolized primarily to two hydroxy metabolites and the glucuronide conjugate of the 5-hydroxy metabolite. With recombinant P450s 1A2, 2C19, 2D6, and 3A4, only the 5-hydroxypomalidomide metabolite was formed in very low amounts,²⁶ and the oxidation rates were significantly lower than in our work (Table 1) (the values reported are semi-quantitative due to lack of authentic standards and represents the relative efficacy of oxidation of pomalidomide by the various P450s). In accord with our observations, no GSH conjugate was detected in the human studies, although the hydroxy metabolites were formed in significant amounts. These results are consistent with our results on the metabolism of pomalidomide (Table 1) and support our hypothesis that extrahepatic P450s may be involved in the species-specific teratogenicity of thalidomide and its analogs. Pomalidomide has been shown to be non-teratogenic in chicken and zebrafish, and lenalidomide was found to be non-teratogenic in rabbits.^{56,57} These findings are in contrast to thalidomide, which is teratogenic in all of these species. This species-specific teratogenicity of thalidomide and its analogs clearly contradicts the cereblon theory¹⁷ because cereblon is ubiquitously expressed. The species-specific teratogenicity does,

however, support the metabolism and reactive intermediate theory.^{13,15} The fact that pomalidomide is not teratogenic in thalidomide-sensitive species is consistent with our observation that no GSH adduct or reactive intermediate is formed during pomalidomide metabolism.

In conclusion, we have shown that 5-hydroxythalidomide is metabolized by P450s 2J2, 2C18, and 4A11 to dihydroxythalidomide. Metabolism by P450 2J2 involves formation of a reactive intermediate that may be responsible for the anti-angiogenic and teratogenic properties of thalidomide. The major metabolite dihydroxythalidomide can be further oxidized to the quinone metabolite, which may be the species responsible for oxidative stress or protein binding, either of which could be the cause for teratogenicity. Although the data presented here provide evidence for the presence of reactive species that may be responsible for imparting toxicity and oxidative stress, a comprehensive metabolic study across species and tissues is required for a better understanding the species-specific teratogenicity of thalidomide and its analogs.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank K. Trisler for assistance in preparation of the manuscript.

Funding Sources

This work was supported in part by the Ministry of Education, Culture, Sports, Science, and Technology of Japan (H.Y.) and United States Public Health Service grants R37 CA090426, R01 ES010546, and P30 ES000267 (F.P.G.).

Abbreviations

CID	collision-induced dissociation
ESI	electrospray ionization
HRMS	high-resolution mass spectrometry
UPLC	ultra-performance liquid chromatography

References

1. Speirs AL. Thalidomide and congenital abnormalities. *Lancet*. 1962; 1:303–305. [PubMed: 13915621]
2. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma: 10 years later. *Blood*. 2008; 111:3968–3977. [PubMed: 18245666]
3. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. *Expt Opin Investig Drugs*. 2005; 14:1411–1418.
4. Zhou S, Wang F, Hsieh TC, Wu JM, Wu E. Thalidomide—a notorious sedative to a wonder anticancer drug. *Curr Med Chem*. 2013; 20:4102–4108. [PubMed: 23931282]
5. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. *Blood*. 2011; 118:899–902. [PubMed: 21622644]
6. Barkin JA, Schonfeld WB, Deshpande AR. Successful use of thalidomide for refractory esophageal Crohn's disease. *Am J Gastroenterol*. 2013; 108:855–857. [PubMed: 23644969]

7. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. *Leukemia Lymphoma*. 2013; 54:683–687. [PubMed: 22966948]
8. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. *OncoTargets Ther*. 2013; 6:531–538.
9. Lacy MQ, McCurdy AR. Pomalidomide. *Blood*. 2013; 122:2305–2309. [PubMed: 23974193]
10. Eriksson T, Bjorkman S, Roth B, Hoglund P. Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. *J Pharm Pharmacol*. 2000; 52:807–817. [PubMed: 10933131]
11. Hoglund P, Eriksson T, Bjorkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. *J Pharmacokin Biopharmac*. 1998; 26:363–383.
12. Reist M, Carrupt PA, Francotte E, Testa B. Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. *Chem Res Toxicol*. 1998; 11:1521–1528. [PubMed: 9860497]
13. Fabro S, Smith RL, Williams RT. Thalidomide as a possible biological acylating agent. *Nature*. 1965; 208:1208–1209. [PubMed: 5870320]
14. Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. *Nat Med*. 1999; 5:582–585. [PubMed: 10229238]
15. Gordon GB, Spielberg SP, Blake DA, Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. *Proc Natl Acad Sci U S A*. 1981; 78:2545–2548. [PubMed: 6941308]
16. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. *Proc Natl Acad Sci U S A*. 1994; 91:4082–4085. [PubMed: 7513432]
17. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. *Science*. 2010; 327:1345–1350. [PubMed: 20223979]
18. Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. *Toxicol Appl Pharmacol*. 1986; 82:175–179. [PubMed: 3945939]
19. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species dependent. *Biochem Pharmacol*. 1998; 55:1827–1834. [PubMed: 9714301]
20. Ando Y, Fuse E, Figg WD. Thalidomide metabolism by the CYP2C subfamily. *Clin Cancer Res*. 2002; 8:1964–1973. [PubMed: 12060642]
21. Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P, Ching LM. Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. *J Pharmacol Exp Ther*. 2004; 310:571–577. [PubMed: 15075384]
22. Chowdhury G, Murayama N, Okada Y, Uno Y, Shimizu M, Guengerich FP, Yamazaki H. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. *Chem Res Toxicol*. 2010; 23:1018–1024. [PubMed: 20443640]
23. Yamazaki H, Suemizu H, Shimizu M, Igaya S, Shibata N, Nakamura M, Chowdhury G, Guengerich FP. *In vivo* formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-hydroxythalidomide in humanized TK-NOG mice. *Chem Res Toxicol*. 2012; 25:274–276. [PubMed: 22268628]
24. Yamazaki H, Suemizu H, Igaya S, Shimizu M, Shibata N, Nakamura M, Chowdhury G, Guengerich FP. *In vivo* formation of a glutathione conjugate derived from thalidomide in humanized uPA-NOG mice. *Chem Res Toxicol*. 2011; 24:287–289. [PubMed: 21299192]
25. Chen N, Wen L, Lau H, Surapaneni S, Kumar G. Pharmacokinetics, metabolism and excretion of [¹⁴C]-lenalidomide following oral administration in healthy male subjects. *Cancer Chemother Pharmacol*. 2012; 69:789–797. [PubMed: 22037879]
26. Hoffmann M, Kasserra C, Reyes J, Schafer P, Kosek J, Capone L, Parton A, Kim-Kang H, Surapaneni S, Kumar G. Absorption, metabolism and excretion of [¹⁴C]pomalidomide in humans following oral administration. *Cancer Chemother Pharmacol*. 2013; 71:489–501. [PubMed: 23203815]

27. Ortiz de Montellano, PR., editor. Cytochrome P450: Structure, Mechanism, and Biochemistry. 3. KluwerAcademic/Plenum Publishers; New York: 2005.
28. Guengerich, FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano, PR., editor. Cytochrome P450: Structure, Mechanism, and Biochemistry. 3. KluwerAcademic/Plenum Publishers; New York: 2005. p. 377-530.
29. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem. 1996; 271:3460–3468. [PubMed: 8631948]
30. Zaphiropoulos PG. Exon skipping and circular RNA formation in transcripts of the human cytochrome P-450 2C18 gene in epidermis and of the rat androgen binding protein gene in testis. Mol Cell Biol. 1997; 17:2985–2993. [PubMed: 9154796]
31. Yengi LG, Xiang O, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron GM, Wolf CR. Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem. 2003; 316:103–110. [PubMed: 12694732]
32. Kitada M, Kamataki T. Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab Rev. 1994; 26:305–323. [PubMed: 8082572]
33. Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP 3rd, Freiwald S, Zientek M, Totah RA. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos. 2010; 38:347–356. [PubMed: 19923256]
34. Kinobe RT, Parkinson OT, Mitchell DJ, Gillam EM. P450 2C18 catalyzes the metabolic bioactivation of phenytoin. Chem Res Toxicol. 2005; 18:1868–1875. [PubMed: 16359177]
35. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999; 285:1276–1279. [PubMed: 10455056]
36. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J, Steenberg C, Falck JR, Moomaw CR, Zeldin DC. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem. 1997; 272:12551–12559. [PubMed: 9139707]
37. Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, Wu S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys. 1996; 330:87–96. [PubMed: 8651708]
38. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int. 2007; 72:683–689. [PubMed: 17597703]
39. Gaedigk A, Baker DW, Totah RA, Gaedigk R, Pearce RE, Vyhldal CA, Zeldin DC, Leeder JS. Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther. 2006; 319:523–532. [PubMed: 16868033]
40. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku zasshi (J Pharmaceutical Soc Japan). 2003; 123:369–375.
41. Yamamoto T, Shibata N, Sukeguchi D, Takashima M, Nakamura S, Toru T, Matsunaga N, Hara H, Tanaka M, Obata T, Sasaki T. Synthesis, configurational stability and stereochemical biological evaluations of (S)- and (R)-5-hydroxythalidomides. Bioorg Med Chem Lett. 2009; 19:3973–3976. [PubMed: 19297157]
42. Guengerich, FP.; Bartleson, CJ. Analysis and characterization of enzymes and nucleic acids. In: Hayes, AW., editor. Principles and Methods of Toxicology. 5. CRC Press; Boca Raton, FL: 2007. p. 1981-2048.
43. Parikh A, Gillam EMJ, Guengerich FP. Drug metabolism by *Escherichia coli* expressing human cytochromes P450. Nat Biotechnol. 1997; 15:784–788. [PubMed: 9255795]
44. Hanna IH, Teiber JF, Kokones KL, Hollenberg PF. Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities. Arch Biochem Biophys. 1998; 350:324–332. [PubMed: 9473308]
45. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH. Functional variant of

- CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. *Circulation*. 2005; 111:63–69. [PubMed: 15611369]
46. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I Evidence for its hemoprotein nature. *J Biol Chem*. 1964; 239:2370–2378. [PubMed: 14209971]
47. Dieckhaus CM, Fernandez-Metzler CL, King R, Krolikowski PH, Baillie TA. Negative ion tandem mass spectrometry for the detection of glutathione conjugates. *Chem Res Toxicol*. 2005; 18:630–638. [PubMed: 15833023]
48. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. Role of quinones in toxicology. *Chem Res Toxicol*. 2000; 13:135–160. [PubMed: 10725110]
49. Kadlubar FF, Miller JA, Miller EC. Hepatic metabolism of *N*-hydroxy-*N*-methyl-4-aminobenzene and other *N*-hydroxy arylamines to reactive sulfuric acid esters. *Cancer Res*. 1976; 36:2350–2359. [PubMed: 819129]
50. Tsen CC. An improved spectrophotometric method for the determination of tocopherols using 4,7-diphenyl-1,10-phenanthroline. *Anal Chem*. 1961; 33:849–851.
51. Wang K, Guengerich FP. Reduction of aromatic amines and heterocyclic aromatic amines by human cytochrome P450 2S1. *Chem Res Toxicol*. 2013; 26:993–1004. [PubMed: 23682735]
52. Stephens TD, Bunde CJW, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. *Biochem Pharmacol*. 2000; 59:1489–1499. [PubMed: 10799645]
53. Hansen JM, Harris KK, Philbert MA, Harris C. Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. *J Pharmacol Exp Ther*. 2002; 300:768–776. [PubMed: 11861780]
54. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Oriowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. *Blood*. 2013; 118:4771–4779. [PubMed: 21860026]
55. Chen C, Wei X, Rao X, Wu J, Yang S, Chen F, Ma D, Zhou J, Dackor RT, Zeldin DC, Wang DW. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. *J Pharmacol Exp Ther*. 2011; 336:344–355. [PubMed: 21030485]
56. Mahony C, Erskine L, Niven J, Greig NH, Figg WD, Vargesson N. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. *Proc Natl Acad Sci U S A*. 2013; 110:12703–12708. [PubMed: 23858438]
57. Christian MS, Laskin OL, Sharper V, Hoberman A, Stirling DI, Latriano L. Evaluation of the developmental toxicity of lenalidomide in rabbits. *Birth Defects Res Part B, Develop Reprod Toxicol*. 2007; 80:188–207.

Figure 1. LC-MS/MS chromatograms and CID spectra showing the oxidation of 5-hydroxythalidomide to dihydroxythalidomide by human P450s 2J2, 2C18, and 4A11

Extracted ion chromatograms of the product ion using the m/z 289 $\rightarrow$ 177 transition of dihydroxythalidomide. (A) P450 2J2, (B) P450 2C18, (C) P450 4A11, (D) MS/MS spectrum of dihydroxythalidomide ($[M-H]^-$ 289). 5-Hydroxythalidomide (100 μ M) was incubated with the human P450 (1.0 μ M) in the presence or absence of an NADPH-generating system, as indicated, for 1 h.

Figure 2. LC-MS/MS chromatograms and CID spectra showing the presence of the GSH conjugate of 5-hydroxythalidomide formed in the presence of recombinant human P450 2J2 Extracted ion chromatogram of the product ion using the m/z 580 $\rightarrow$ 451 transition of 5-hydroxythalidomide-GSH conjugate. (A) P450 2J2 in the presence and absence of NADPH. (B) MS/MS spectrum of GSH conjugate of 5-hydroxythalidomide ($[M+H]^+$ 580). 5-Hydroxythalidomide (100 μ M) was incubated with human P450 2J2 (1.0 μ M) and GSH (5 mM) in the presence or absence of an NADPH-generating system, as indicated, for 1 h.

Figure 3. LC-MS/MS chromatograms and CID spectrum showing the oxidation of dihydroxythalidomide to the quinone product by P450 3A4

(A) Extracted ion chromatogram of the quinone metabolite using the molecular ion m/z 287 (top chromatogram) and the characteristic product ion m/z 175 (bottom chromatogram). (B) MS/MS spectrum of the quinone metabolite ($[M-H]^-$ 287) showing the characteristic m/z 175 and 244 fragment ions.

Figure 4. LC-MS/MS chromatograms and CID spectrum showing the presence of the GSH conjugates of 5-hydroxythalidomide formed in the presence of GSH

Extracted ion chromatogram of the product ion using the m/z 596 $\rightarrow$ 467 transition of the dihydroxythalidomide-GSH conjugate. (A) P450 3A4, (B) MS/MS spectrum of the dihydroxythalidomide-GSH conjugate ($[M+H]^+$ 596) eluting at t_R 2.4 min, (C) P450 2J2, (D) MS/MS spectrum of the dihydroxythalidomide-GSH conjugate ($[M+H]^+$ 596) eluting at t_R 3.0 min. 5-Hydroxythalidomide (200 μ M) was incubated with P450 3A4 bicistronic membranes (1.0 μ M P450) or P450 2J2 Supersomes[®] (1.0 μ M P450) in the presence of GSH (5 mM) and an NADPH-generating system for 3 h.

Figure 5. LC-MS/MS chromatograms and CID spectrum showing the oxidation of pomalidomide to the hydroxypomalidomide metabolite by human liver microsomes and P450s 2C19, 2J2, and 3A4

(A) Extracted ion chromatogram of the hydroxypomalidomide metabolite using the characteristic m/z 288 $\rightarrow$ 176 transition. (B) MS/MS spectrum of the hydroxypomalidomide product ($[M-H]^-$ 288) showing the characteristic m/z 176 and 245 fragmentations.

Scheme 1.
Proposed metabolic pathway of thalidomide.

Scheme 2.

Proposed mechanism for non-enzymatic oxidation of 5-hydroxythalidomide.

Scheme 3.
Proposed pathway of metabolism of pomalidomide.

Table 1

Kinetic parameters for aminophthalidimide ring hydroxylation of pomalidomide by P450s

P450	k_{cat} (min^{-1})	K_{m} (mM)	$k_{\text{cat}}/K_{\text{m}}$ ($\text{min}^{-1} \text{mM}^{-1}$)
2C19	0.52 ± 0.062	0.82 ± 0.17	0.63
3A4	0.05 ± 0.004	0.26 ± 0.06	0.19
2J2	0.02 ± 0.001	0.14 ± 0.03	0.14